Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Verici Dx (VRCI) Share Price

Price 0.275p on 30-07-2026 at 18:35:07
Change -0.05p -14.29%
Buy 0.30p
Sell 0.25p
Last Trade: Buy 900.00 at 0.30p
Day's Volume: 3,757,420
Last Close: 0.30p
Open: 0.35p
ISIN: GB00BM8HZD43
Day's Range 0.30p - 0.30p
52wk Range: 0.275p - 0.95p
Market Capitalisation: £6.86m
VWAP: 0.275632p
Shares in Issue: 2.29b

Verici Dx (VRCI) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 900 0.30p Suspected BUY Trade
16:40:41 - 30-Jul-26
Sell* 1,500,000 0.25p Ordinary
16:38:16 - 30-Jul-26
Sell* 200,000 0.2749p Ordinary
16:28:52 - 30-Jul-26
Sell* 22,090 0.265p Ordinary
16:13:30 - 30-Jul-26
Buy* 1 0.30p Ordinary
16:10:17 - 30-Jul-26
Sell* 17,780 0.265p Ordinary
16:05:30 - 30-Jul-26
Buy* 200,000 0.28p Ordinary
16:03:16 - 30-Jul-26
Buy* 150,000 0.2849p Ordinary
15:59:22 - 30-Jul-26
Buy* 39,990 0.289p Ordinary
15:37:08 - 30-Jul-26
Sell* 200,000 0.26p Ordinary
15:37:00 - 30-Jul-26
See more Verici Dx trades

Verici Dx (VRCI) Share Price History

Time period:
to
Date Open High Low Close Volume
30th Jul 2026 (Thu) 0.35 0.30 0.30 0.30 3,757,420
29th Jul 2026 (Wed) 0.35 0.35 0.35 0.35 37,006
28th Jul 2026 (Tue) 0.35 0.35 0.35 0.35 154,287
27th Jul 2026 (Mon) 0.35 0.35 0.35 0.35 504,483
24th Jul 2026 (Fri) 0.35 0.35 0.35 0.35 244,975
23rd Jul 2026 (Thu) 0.35 0.35 0.35 0.35 308,973
22nd Jul 2026 (Wed) 0.35 0.35 0.35 0.35 36,158
21st Jul 2026 (Tue) 0.35 0.35 0.35 0.35 26,037
20th Jul 2026 (Mon) 0.35 0.35 0.35 0.35 275,504
17th Jul 2026 (Fri) 0.35 0.35 0.35 0.35 420
16th Jul 2026 (Thu) 0.35 0.35 0.35 0.35 0
15th Jul 2026 (Wed) 0.35 0.35 0.35 0.35 250,902
14th Jul 2026 (Tue) 0.35 0.35 0.35 0.35 35,320
13th Jul 2026 (Mon) 0.35 0.35 0.35 0.35 195,121
10th Jul 2026 (Fri) 0.35 0.35 0.35 0.35 332,000
9th Jul 2026 (Thu) 0.325 0.35 0.325 0.35 20,306
8th Jul 2026 (Wed) 0.375 0.375 0.325 0.35 5,132,795
7th Jul 2026 (Tue) 0.375 0.375 0.375 0.375 518,943
6th Jul 2026 (Mon) 0.375 0.375 0.375 0.375 1,423,000
3rd Jul 2026 (Fri) 0.375 0.375 0.375 0.375 289,247
2nd Jul 2026 (Thu) 0.375 0.375 0.375 0.375 2,223,634
1st Jul 2026 (Wed) 0.375 0.375 0.375 0.375 1,712,430
See more Verici Dx price history

Verici Dx (VRCI) Regulatory News

Date Source Headline
28th Jul 2026 2:20 pm RNS Result of AGM
6th Jul 2026 7:00 am RNS-R Investor presentation
1st Jul 2026 11:22 am RNS Holding(s) in Company
29th Jun 2026 7:00 am RNS Final results for the year ended 31 December 2025
25th Jun 2026 4:08 pm RNS Holding(s) in Company
24th Jun 2026 5:24 pm RNS Holding(s) in Company
24th Jun 2026 4:34 pm RNS Holding(s) in Company
24th Jun 2026 12:37 pm RNS Holding(s) in Company
24th Jun 2026 11:13 am RNS Holding(s) in Company
24th Jun 2026 9:06 am RNS Holding(s) in Company
See more Verici Dx regulatory news

Verici Dx (VRCI) Share News

EARNINGS: Safestay annual loss widens; Wynnstay ups interim dividend

29th Jun 2026 11:52

(Alliance News) - The following is a round-up of earnings of London-listed companies, issued on Monday and not separately reported by Alliance News: Read More

TRADING UPDATES: Tullow Oil makes partial notes repayment

24th Jun 2026 13:40

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More

TRADING UPDATES: Unicorn Mineral; Helix Exploration agree acquisitions

8th Jun 2026 15:59

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on xxxday and not separately reported by Alliance News: Read More

IN BRIEF: Verici Dx says study validates PTRA in kidney transplants

19th May 2026 16:16

Verici Dx PLC - Cardiff, Wales-based developer of advanced clinical diagnostics for organ transplants - Announces the publication of a peer-reviewed clinical validation study of its pre-transplant rejection assessment test, which is commercially marketed by Thermo Fisher Scientific Inc. Says the test outperformed conventional risk assessment tools in the ability to predict early acute rejection in the first two months following a kidney transplant, which enables clinicians to identify patients who may benefit from the safe minimisation of therapy while effectively managing the risk of early rejection. Says current methods, which involve standardised immunosuppressive regimens with more aggressive therapy for patients seen as high-risk, "have limited predictive value, which can lead to unnecessary over-suppression and risks related to toxicity, infections and malignancy." Read More

WINNERS & LOSERS: Riverstone redeems shares; IQE raises GBP513 million

28th Apr 2026 11:20

(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Tuesday. Read More

See more Verici Dx news
FTSE 100 Latest
Value10,897.27
Change-11.14

Login to your account

Forgot Password?

Not Registered